| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg | ||
| Other Sizes |
| ln Vitro |
Treatment of breast cancer cells with SLLN-15 (0, 1, 5, 10, 25 μM) for 24 hours significantly reduces their total cell viability in a dose-dependent manner[1]. SLLN-15 (100 nM and 1000 nM, 7 days) can suppress multiple breast cancer cell lines' capacity to form colonies in an equivalent manner[1]. Overall, SLLN-15 stimulates autophagy and autophagic flux in TNBC cell lines MDA-MB-231 and BT-20, resulting in a dose-dependent anti-proliferative effect. AKT-MTOR signaling is selectively inhibited in response to this stimulation.
|
|---|---|
| ln Vivo |
SLLN-15 (30 mg/kg, PO, three times a week) suppresses the metastasis of TNBC cells as well as the growth of TNBC in animal models[1]. In mice with TNBC, oral SLLN-15 exhibits strong anticancer and anti-metastasis activity overall[1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: TNBC cell lines BT-20 and MDA-MB-231. Tested Concentrations: 0, 1, 5, 10, 25 μM. Incubation Duration: 24 hrs (hours). Experimental Results: Inhibited the proliferation of two TNBC cell lines, BT-20 and MDA -MB-231. Cell Viability Assay[1] Cell Types: TNBC cell lines (MDA-MB-231, BT-20, 4T1, MDA-MB-468), MCF-7 (ERBB2-), SKBR-3 (ERBB2+ ) and HEK293T. Tested Concentrations: 100 nM and 1000 nM. Incubation Duration: 7 days. Experimental Results: Equally inhibited the colony formation abilities of several breast cancer cell lines. |
| Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse: or SCID (severe combined immunodeficient) mouse transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA- MB-231 cells (1 of the number of lung metastases as visualized.
|
| References |
[1]. Chang CH, et al. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy. 2019 Mar 1:1-15.
|
| Molecular Formula |
C19H23N7SE2
|
|---|---|
| Molecular Weight |
507.35
|
| CAS # |
2403650-93-9
|
| SMILES |
N1C2C(=NC(NC3=CC=C(N4CC[Se]CC4)C=C3)=NC=2N[C@H]2CC[Se]C2)NC=1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9710 mL | 9.8551 mL | 19.7103 mL | |
| 5 mM | 0.3942 mL | 1.9710 mL | 3.9421 mL | |
| 10 mM | 0.1971 mL | 0.9855 mL | 1.9710 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
